Literature DB >> 27113604

Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes.

H A Jinnah1, Emily Goodmann2, Ami R Rosen2, Marian Evatt2,3, Alan Freeman2, Stewart Factor2.   

Abstract

Botulinum toxin (BoNT) is highly effective in the treatment of cervical dystonia (CD), yet a significant proportion of patients report low levels of satisfaction following treatment and fail to follow up for repeated treatments. The goal of this study was to determine the reasons that some patients have unsatisfactory responses. A total of 35 subjects who came to our center requesting alternative treatments due to unsatisfactory responses following BoNT treatment for CD were evaluated. Included were 26 women and 9 men with an average age of 57.1 years (range 25-82 years), and an average duration of illness of 12.5 years (range 1-55 years). Details of unsatisfactory BoNT treatments were methodically collected by a movement specialist using a standardized intake form, including provider subspecialty, product used, the number of satisfactory or unsatisfactory trials, doses given, specific muscles treated, the use of electromyographic guidance, side effects, and tests of resistance. The specialist then provided repeat treatments if indicated, and followed each case until the reasons for unsatisfactory outcomes could be determined. Multiple reasons for unsatisfactory outcomes were found. They included suboptimal BoNT doses, suboptimal muscle targeting, intolerable side effects, complex movement patterns, discordant perceptions, and incorrect diagnoses. Only one patient was functionally resistant to BoNT. Of 32 subjects who received repeat BoNT treatments, 25 (78 %) achieved satisfactory responses after revision of the original treatment plan. These results indicate that the majority of unsatisfactory responses to BoNT treatment of CD were caused by correctible factors and imply a need for improved education regarding optimal treatment methods.

Entities:  

Keywords:  Botulinum toxin; Treatment failure; Treatment resistance

Mesh:

Substances:

Year:  2016        PMID: 27113604      PMCID: PMC4904718          DOI: 10.1007/s00415-016-8136-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  38 in total

1.  Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.

Authors:  G-Y R Hsiung; S K Das; R Ranawaya; A-L Lafontaine; O Suchowersky
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

2.  Clinical subtypes of anterocollis in parkinsonian syndromes.

Authors:  Gonzalo J Revuelta; Michael Benatar; Alan Freeman; Thomas Wichmann; H A Jinnah; Mahlon R DeLong; Stewart A Factor
Journal:  J Neurol Sci       Date:  2011-11-30       Impact factor: 3.181

3.  Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A.

Authors:  A Brashear; K Bergan; J Wojcieszek; E R Siemers; W Ambrosius
Journal:  Mov Disord       Date:  2000-01       Impact factor: 10.338

4.  Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle.

Authors:  Joanna M Flowers; Lucy A Hicklin; Marie-Helene Marion
Journal:  Mov Disord       Date:  2011-09-12       Impact factor: 10.338

5.  Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).

Authors:  Joseph Jankovic; Charles H Adler; David Charles; Cynthia Comella; Mark Stacy; Marc Schwartz; Aubrey Manack Adams; Mitchell F Brin
Journal:  J Neurol Sci       Date:  2014-12-27       Impact factor: 3.181

6.  Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.

Authors:  Chandra Coleman; Jean Hubble; Joseph Schwab; Jean-Luc Beffy; Philippe Picaut; Carles Morte
Journal:  Int J Neurosci       Date:  2012-05-11       Impact factor: 2.292

7.  The spread of primary late-onset focal dystonia in a long-term follow up study.

Authors:  Marina Svetel; Tatjana Pekmezovic; Aleksandra Tomic; Nikola Kresojevic; Vladimir S Kostic
Journal:  Clin Neurol Neurosurg       Date:  2015-02-28       Impact factor: 1.876

8.  Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia.

Authors:  Joaquim J Ferreira; Carlo Colosimo; Roongroj Bhidayasiri; Maria Jose Marti; Pascal Maisonobe; Savary Om
Journal:  Parkinsonism Relat Disord       Date:  2014-11-20       Impact factor: 4.891

9.  Blepharospasm plus Cervical Dystonia with Predominant Anterocollis: A Distinctive Subphenotype of Segmental Craniocervical Dystonia?

Authors:  Olga Waln; Mark S Ledoux
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2011-08-10

10.  Botulinum toxin therapy for cervical dystonia: the science of dosing.

Authors:  Virgilio Gerald H Evidente; Eric J Pappert
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-11-12
View more
  12 in total

1.  The role of polymyography in the treatment of cervical dystonia.

Authors:  Roberto Erro; Kailash P Bhatia; Marcello Esposito; Carla Cordivari
Journal:  J Neurol       Date:  2016-06-17       Impact factor: 4.849

Review 2.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

3.  Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.

Authors:  Olivia Samotus; Jack Lee; Mandar Jog
Journal:  J Neurol       Date:  2018-03-20       Impact factor: 4.849

Review 4.  Anatomy and cervical dystonia : "Dysfunction follows form".

Authors:  L Tatu; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2016-09-13       Impact factor: 3.575

Review 5.  Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?

Authors:  H A Jinnah; Cynthia L Comella; Joel Perlmutter; Codrin Lungu; Mark Hallett
Journal:  Toxicon       Date:  2017-09-06       Impact factor: 3.033

Review 6.  Immunogenicity Associated with Botulinum Toxin Treatment.

Authors:  Steven Bellows; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2019-08-26       Impact factor: 4.546

Review 7.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

8.  Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis.

Authors:  Olivia Samotus; Jack Lee; Mandar Jog
Journal:  Toxins (Basel)       Date:  2021-04-08       Impact factor: 4.546

9.  Management of Secondary Poor Response to Botulinum Toxin in Cervical Dystonia: A Multicenter Audit.

Authors:  Harry Tucker; Foster Osei-Poku; Diane Ashton; Rachael Lally; Aaron Jesuthasan; Anna Latorre; Kailash P Bhatia; Jane E Alty; Christopher Kobylecki
Journal:  Mov Disord Clin Pract       Date:  2021-03-16

10.  The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.

Authors:  Harald Hefter; Isabelle Schomaecker; Max Schomaecker; Dietmar Rosenthal; Sara Samadzadeh
Journal:  Toxins (Basel)       Date:  2021-07-16       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.